Torcetrapib is a cholesterol ester transfer protein (CETP) inhibitor that exhibits anti-atherosclerotic and anti-diabetic activities. In vivo, this compound increases levels of HDL and glucose uptake and decreases levels of triglycerides, free fatty acids, blood glucose, and plasma insulin. Torcetrapib exhibits mixed results in clinical settings due to potential off-target actions on signaling pathways involving IL-2, PDGFR, and HGFR.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.